BC Cancer's Dr. Florian Kuchenbauer and Dr. François Bénard, in collaboration with TRIUMF Innovations and led by Dr. Robert Britton from Simon Fraser University, have secured a grant from the Centre for Probe Development and Commercialization (CPDC) to conduct ground-breaking research in cancer imaging.
Kwangjin Park (Hoodless Lab) has been awarded the Canadian Institutes of Health Research 2022 Postdoctoral Fellowship Award for the project titled, "Roles of the Lysine Methyl Transferase (KMT) 2D in hepatocyte cell identity and hepatocellular carcinoma (HCC) progression." Read the announcement here.
A recent study conducted by TFRI-funded researchers at BC Cancer sheds light on the cause behind the different outcomes of patients with diffuse large B cell lymphoma (DLBCL) who experienced a relapse in their disease. The study confirmed that patients whose cancer relapses shortly after treatment typically have poor responses to additional chemotherapy-based treatment. However, when the relapse occurs more than two years from the time of diagnosis, the outcomes to chemotherapy are significantly better.
BC Cancer scientist Dr. Ly Vu is one of 11 recipients of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research. This new granting program, developed by the V Foundation for Cancer Research, sees $8 million in funding invested in cancer research being led by women scientists. Dr.
Dr. Joseph Lau is working to develop the next generation of radiopharmaceuticals for both diagnostic and therapeutic purposes. Radiopharmaceuticals are radioactive compounds used in cancer care. From a diagnostic perspective, his work focusses on making these radioactive agents better able to detect and visualize cancers in the body. From a treatment perspective this helps oncologists determine if a cancer is operable, delineates margins for radiation planning or select targeted-therapies based on molecular properties of cancer.
Dr. Carol Chen is dedicated to understanding the complexities and finding innovative solutions to high-grade gliomas (HGGs); a particularly aggressive form of brain cancer affecting children and young adults. The new BC Cancer scientist, who joined the Terry Fox Laboratory in 2023, is focused on understanding how mutations in certain proteins, called histones or histone-modifying enzymes, contribute to the development of HGGs.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.